DNA methylation profiling of well‐differentiated thyroid cancer uncovers markers of recurrence free survival
暂无分享,去创建一个
E. Lerma | X. Matías-Guiu | M. Peinado | D. Mauricio | M. Puig-Domingo | E. Castelblanco | L. Inglada-Perez | I. Capel | M. Robledo | V. Mancikova | M. Currás-Freixes | J. Reverter | E. Castellà | M. Bella | R. Buj | A. Díez | A. A. Cubas | Francisco Xavier Maravall | Mireia Jordà | V. Mančíková
[1] Gustavo F. Bayón,et al. DNA methylation signatures identify biologically distinct thyroid cancer subtypes. , 2013, The Journal of clinical endocrinology and metabolism.
[2] Timothy E. Reddy,et al. Dynamic DNA methylation across diverse human cell lines and tissues , 2013, Genome research.
[3] M. Pelizzo,et al. Differential gene expression of medullary thyroid carcinoma reveals specific markers associated with genetic conditions. , 2013, The American journal of pathology.
[4] Q. Tao,et al. Epigenetic silencing of the 3p22 tumor suppressor DLEC1 by promoter CpG methylation in non-Hodgkin and Hodgkin lymphomas , 2012, Journal of Translational Medicine.
[5] T. H. van der Kwast,et al. Quantitative DNA methylation analysis of genes coding for kallikrein-related peptidases 6 and 10 as biomarkers for prostate cancer , 2012, Epigenetics.
[6] S. Lam,et al. Genome-scale analysis of DNA methylation in lung adenocarcinoma and integration with mRNA expression , 2012, Genome research.
[7] M. Hoque,et al. Correlation between BRAF mutation and promoter methylation of TIMP3, RARβ2 and RASSF1A in thyroid cancer , 2012, Epigenetics.
[8] P. Soares,et al. mTOR pathway overactivation in BRAF mutated papillary thyroid carcinoma. , 2012, The Journal of clinical endocrinology and metabolism.
[9] L. D. White,et al. Genomic Hypomethylation in the Human Germline Associates with Selective Structural Mutability in the Human Genome , 2012, PLoS genetics.
[10] H. Kitchener,et al. The Dynamics and Prognostic Potential of DNA Methylation Changes at Stem Cell Gene Loci in Women's Cancer , 2012, PLoS genetics.
[11] Andreu Alibés,et al. HumMeth27QCReport: an R package for quality control and primary analysis of Illumina Infinium methylation data , 2011, BMC Research Notes.
[12] P. Hou,et al. Genome-wide alterations in gene methylation by the BRAF V600E mutation in papillary thyroid cancer cells. , 2011, Endocrine-related cancer.
[13] M. Borrello,et al. Evidence of oncogene-induced senescence in thyroid carcinogenesis. , 2011, Endocrine-related cancer.
[14] Ratnesh K Singh,et al. Inactivation of CHEK1 and EI24 is associated with the development of invasive cervical carcinoma: Clinical and prognostic implications , 2011, International journal of cancer.
[15] Marina N. Nikiforova,et al. Molecular genetics and diagnosis of thyroid cancer , 2011, Nature Reviews Endocrinology.
[16] Gavin Sherlock,et al. DNA methylation profiling reveals novel biomarkers and important roles for DNA methyltransferases in prostate cancer. , 2011, Genome research.
[17] Thomas Lengauer,et al. A DNA methylation fingerprint of 1628 human samples. , 2011, Genome research.
[18] Xiao Zhang,et al. Comparison of Beta-value and M-value methods for quantifying methylation levels by microarray analysis , 2010, BMC Bioinformatics.
[19] Hiroyuki Yamamoto,et al. IGFBP7 is a p53-responsive gene specifically silenced in colorectal cancer with CpG island methylator phenotype. , 2010, Carcinogenesis.
[20] P. Laird,et al. Analysis of the Association between CIMP and BRAFV600E in Colorectal Cancer by DNA Methylation Profiling , 2009, PloS one.
[21] K. Gunderson,et al. Genome-wide DNA methylation profiling using Infinium® assay. , 2009, Epigenomics.
[22] Ramón Díaz-Uriarte,et al. Pomelo II: finding differentially expressed genes , 2009, Nucleic Acids Res..
[23] L. Horvath,et al. DLEC1 and MLH1 promoter methylation are associated with poor prognosis in non-small cell lung carcinoma , 2008, British Journal of Cancer.
[24] G. Robertson,et al. Akt3 and mutant V600E B-Raf cooperate to promote early melanoma development. , 2008, Cancer research.
[25] B. Zhu,et al. Do Benign Thyroid Nodules Have Malignant Potential? An Evidence-Based Review , 2008, World Journal of Surgery.
[26] J. Dopazo,et al. Molecular profiling related to poor prognosis in thyroid carcinoma. Combining gene expression data and biological information , 2008, Oncogene.
[27] D. Faller,et al. Loss of putative tumor suppressor EI24/PIG8 confers resistance to etoposide , 2007, FEBS letters.
[28] Minoru Toyota,et al. Integrated genetic and epigenetic analysis identifies three different subclasses of colon cancer , 2007, Proceedings of the National Academy of Sciences.
[29] M. Santoro,et al. Association of BRAF V600E mutation with poor clinicopathological outcomes in 500 consecutive cases of papillary thyroid carcinoma. , 2007, The Journal of clinical endocrinology and metabolism.
[30] J. Califano,et al. Association of aberrant methylation of tumor suppressor genes with tumor aggressiveness and BRAF mutation in papillary thyroid cancer , 2006, International journal of cancer.
[31] M. Fraga,et al. Chromosomal instability correlates with genome-wide DNA demethylation in human primary colorectal cancers. , 2006, Cancer research.
[32] P. Laird,et al. CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer , 2006, Nature Genetics.
[33] S. Asa,et al. Pathogenetic mechanisms in thyroid follicular-cell neoplasia , 2006, Nature Reviews Cancer.
[34] P. Ladenson,et al. BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. , 2005, The Journal of clinical endocrinology and metabolism.
[35] David E. Misek,et al. Molecular classification of papillary thyroid carcinoma: distinct BRAF, RAS, and RET/PTC mutation-specific gene expression profiles discovered by DNA microarray analysis , 2005, Oncogene.
[36] J. Shay,et al. BRAFE600-associated senescence-like cell cycle arrest of human naevi , 2005, Nature.
[37] W. Hiddemann,et al. Prognostic impact of RT-PCR-based quantification of WT1 gene expression during MRD monitoring of acute myeloid leukemia , 2005, Leukemia.
[38] E. Diamandis,et al. The emerging roles of human tissue kallikreins in cancer , 2004, Nature Reviews Cancer.
[39] P. Ladenson,et al. Methylation of the thyroid-stimulating hormone receptor gene in epithelial thyroid tumors: a marker of malignancy and a cause of gene silencing. , 2003, Cancer research.
[40] R. Schreiber,et al. Cancer immunoediting: from immunosurveillance to tumor escape , 2002, Nature Immunology.
[41] O. Hrusak,et al. Real-time quantitative PCR detection of WT1 gene expression in children with AML: prognostic significance, correlation with disease status and residual disease detection by flow cytometry , 2002, Leukemia.
[42] G. Pfeifer,et al. Frequent epigenetic silencing of the CpG island promoter of RASSF1A in thyroid carcinoma. , 2002, Cancer research.
[43] M. Yatin,et al. Restoration of iodide uptake in dedifferentiated thyroid carcinoma: relationship to human Na+/I-symporter gene methylation status. , 1999, The Journal of clinical endocrinology and metabolism.
[44] D. Woods,et al. Senescence of human fibroblasts induced by oncogenic Raf. , 1998, Genes & development.
[45] E Gabrielson,et al. Aberrant methylation of p16(INK4a) is an early event in lung cancer and a potential biomarker for early diagnosis. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[46] M. Medvedovic,et al. Studies of allelic loss in thyroid tumors reveal major differences in chromosomal instability between papillary and follicular carcinomas. , 1998, The Journal of clinical endocrinology and metabolism.
[47] P. Laird,et al. Genome-scale analysis of aberrant DNA methylation in colorectal cancer. , 2012, Genome research.
[48] Brad T. Sherman,et al. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources , 2008, Nature Protocols.
[49] S. Formenti,et al. Recombinant alpha2(IV)NC1 domain inhibits tumor cell-extracellular matrix interactions, induces cellular senescence, and inhibits tumor growth in vivo. , 2005, The American journal of pathology.
[50] S. Formenti,et al. Recombinant (cid:2) 2(IV)NC1 Domain Inhibits Tumor Cell-Extracellular Matrix Interactions, Induces Cellular Senescence, and Inhibits Tumor Growth in Vivo , 2005 .
[51] M. Saji,et al. Carcinoma Overexpression and Overactivation of Akt in Thyroid Updated , 2001 .